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a b s t r a c t
The present systematic review aims to discuss infl iximab-induced autoantibodies and sub-
sequent onset of systemic lupus erythematosus (SLE) through the analyses of primary re-
ports measuring autoantibodies both before and after the administration of infl iximab for 
the treatment of several diseases – e.g., rheumatoid arthritis, ankylosing spondylitis, pso-
riatic arthritis, and Crohn’s disease. Our literature search was performed in nine databases 
– PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, EMBASE, Scielo and 
LILACS, and the search query retrieved 998 primary reports, from which 24 articles were 
selected and further narrowed down to 14, based on our inclusion criteria. Two indepen-
dent reviewers performed the article selection and a third reviewer solved discrepancies. 
Our inclusion criteria comprised primary reports of phase IV clinical trials with duration of 
at least three months. In total, 760 patients were evaluated and the most prevalent assays 
performed in the studies were anti-nuclear antibodies (ANA), anti-double stranded DNA 
antibodies (anti-dsDNA), and antibodies to saline-extracted antigens (ENA panel). Of all 
patients evaluated, 10 (1.3%) showed clinical signs and laboratorial evidence of infl iximab-
induced SLE.
© 2013 Elsevier Editora Ltda. All rights reserved.
Revisão sistemática da indução de autoanticorpos e lúpus eritematoso 
pelo infl iximabe
Palavras-chave:
Infl iximabe
Terapia biológica
Autoanticorpos
r e s u m o
Nesta revisão sistemática abordamos  a indução de autoanticorpos e lúpus eritematoso 
pelo infliximabe, analisando estudos que dosaram vários autoanticorpos antes e após o uso 
do infliximabe em diversas doenças (artrite reumatoide, espondilite anquilosante, artrite 
psoriásica e doença de Crohn). Nossa busca foi realizada em nove bases de dados (Pub-
Med, ScienceDirect, Scopus, Web of Knowledge, Scirus, Cochrane, EMBASE, Scielo e LILACS). 
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Foram encontradas 998 referências; 24 artigos foram separados na íntegra, dos quais 10 
foram excluídos por não entrarem em nossos critérios de seleção. A escolha dos artigos 
foi realizada por dois revisores, e as divergências foram resolvidas por um terceiro revi-
sor. Incluímos estudos de fase IV, com no mínimo três meses de duração. No total foram 
estudados 760 pacientes; o fator antinuclear, o anticorpo anti-DNA de dupla hélice e os 
antígenos extraídos pela salina foram os mais verificados. De todos os pacientes, apenas 10 
(1,3%) apresentaram manifestações clínico-laboratoriais de lúpus induzido por infliximabe.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
The advent of biological therapy has changed the treatment 
profi le of autoimmune diseases. However, despite more than 
a decade using anti-tumor necrosis factor (anti-TNF) agents, 
many questions still remain. One of the most important is 
the association between autoantibody induction and cer-
tain diseases such as drug-induced lupus (DIL). The present 
study is a systematic review on the role of infl iximab as an 
autoantibody inducer, discussing what has been published 
in this regard. 
Regarding immune responses after antigen stimulation, 
according to the local cytokine environment, T CD4 + naïve 
proliferate and differentiate into different effector subtypes 
with their own characteristics (Th1, Th2, Th3, Treg, Th17) de-
termined by the profi le of the produced cytokines and the 
functional properties. Thus, Th1 or Th2 profi le cytokines guide 
the development of their respective pathway, inhibiting the 
opposite pattern expression. 
Thus, once the immune response to the Th1 pattern is 
polarized, the Th2 pathway will be inhibited, and vice versa.1 
As the anti-TNF agents inhibit Th1 response, there could be 
an increase in the occurrence of Th2 profi le autoimmune 
phenomena, such as systemic lupus erythematosus (SLE). 
However, the occurrence of SLE has been only occasionally 
reported, although the production of antinuclear factors and 
autoantibodies is much more frequent.2-4 It is noteworthy how 
diffi culty it is to prove DIL caused by a particular medication, 
as symptoms must improve with the drug withdrawal (days 
to weeks after discontinuation) and reappear or reaggravate 
the disease by restarting it. However, it is diffi cult to do so 
in clinical practice. In addition, the medication should have 
been employed for at least a month, but perhaps these data 
do not apply to biological agents.5 
When one talks about DIL, one must remember that the 
symptoms are somewhat different from those seen in SLE, with 
arthralgia, myalgia, fever, malaise and serositis being more 
common, whereas kidney lesions and neurological disorders 
are uncommon. The classic skin manifestations of SLE such 
as malar rash and discoid lesions are uncommon in DIL, with 
nonspecifi c lesions (erythema nodosum and purpura) being 
more frequent in this case. However, cases of lupus induced by 
anti-TNF, especially infl iximab, can show classic lesions such 
as malar rash and discoid lupus.6 From the laboratory point 
of view, reactive antinuclear antibodies (ANA) are commonly 
found, as well as leukopenia, thrombocytopenia, anemia and 
anti-histone antibodies. The latter, in fact, is a nonspecifi c one, 
as it can also be observed in SLE.7 Laboratory fi ndings may take 
several months to disappear after drug withdrawal.8 
Although anti-TNF therapy favors the appearance of auto-
antibodies, clinical autoimmune complications are rare.9 In re-
lation to the production of autoantibodies by anti-TNF agents, 
some mechanisms have been proposed: a) as the anti-TNF re-
duces acute phase proteins and phagocytosis of apoptotic cell 
debris, the persistence of nuclear debris would be immuno-
genic, which would lead to autoantibody synthesis induction;10 
b) Anti-TNF could induce the apoptosis of TNF-producing cell 
and inhibit clearance of these apoptotic cell debris, which in 
turn would be immunogenic and induce the synthesis of au-
toantibodies.11 In this review we chose to use only infl iximab, 
as considering that this drug is a chimeric anti-TNF agent, it 
contains an immunogenic murine portion, whereas the other 
biological agents of this class are human, thus having a lower 
chance of inducing autoimmune phenomena. 
Methods
This systematic review was performed according to the PRIS-
MA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) guidelines.12
Databases and search strategies
The search was carried out in nine databases (PubMed, Sci-
enceDirect, Scopus, Web of Knowledge, Scirus, Cochrane, EM-
BASE, LILACS and SciELO, including the so-called gray litera-
ture (Scirus). There were no language restrictions. All articles 
found until January 2012 were evaluated. A librarian with ex-
perience in systematic reviews helped to prepare the follow-
ing search strategy based on the PubMed database: #2 Search 
infl iximab; #4 Search (“autoantibodies”[MeSH Terms]) OR “au-
toimmune diseases”[MeSH Terms]) OR “autoimmunity”[MeSH 
Terms]08:21:05359160; #7 Search (“arthritis, psoriatic/drug 
therapy”[MeSH Terms]) OR “psoriasis/drug therapy”[MeSH 
Terms]) OR “spondylitis, ankylosing/drug therapy”[MeSH 
Terms]) OR “Crohn’s disease/drug therapy”[MeSH Terms]) OR 
“proctocolitis/drug therapy”[MeSH Terms]) AND “arthritis, 
rheumatoid/drug therapy”[MeSH Terms]08:24:33805. Equiva-
lent strategies were used in other databases.
The electronic search database was created with the help of 
the Web endnote software. Duplicate citations were excluded. 
Relevant titles and abstracts were selected by two reviewers 
(JLP Vaz, Pereira AC) and disagreements were resolved by con-
sensus or by a third reviewer (Andrade CAF), when necessary. 
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Figure 1 – Flowchart showing the study selection process.
998 references identified in 9 databases
919 abstracts excluded (did not meet inclusion criteria)
79 abstracts selected by the title
24 articles selected for assessment by the authors
14 articles met inclusion criteria of this systematic review
10 articles excluded:
2 review articles
2 articles used other biologicals before
2 articles evaluated diagnostic methods for anti-DNAds
2 articles included several biologicals in the same sample
1 article did not evaluate patients separately
1 article evaluated autoantibodies before infliximab only
Selection criteria and data extraction
Only articles related to clinical trials and cohort studies that 
included the measurement of autoantibodies before and after 
the use of infl iximab were selected; case reports and review 
articles were excluded. Only studies with a minimum dura-
tion of three months, in which infl iximab was the fi rst bio-
logical agent used and patients were adult individuals aged 18 
and older were accepted. Articles that included patients with 
more than one autoimmune disease were excluded. Among 
the diseases, rheumatoid arthritis (RA), ankylosing spondyli-
tis (AS), psoriatic arthritis (PA), psoriasis, Crohn’s disease and 
ulcerative colitis were selected. These diseases were chosen 
because infl iximab can be used in any of these diseases by 
adult patients. 
We chose to compare autoantibody variability only (before 
and after use of infl iximab), regardless of the titration. Studies 
that included the following antibodies/methods were accept-
ed: antinuclear antibodies (ANA) by indirect immunofl uores-
cence on HEp-2 cells (regardless of the cutoff); anticardiolipin 
(aCL) by ELISA; anti-double-stranded (anti-dsDNA) or anti-na-
tive DNA (anti-nDNA) by indirect immunofl uorescence using 
as substrate Crithidia luciliae and other autoantibodies [saline-
extracted antigens (total anti-ENA), anti-histone, anti-single 
stranded DNA (anti-ssDNA), anti-Ro, anti-La, anti-Sm , anti-ri-
bonucleoprotein (anti-RNP), anti-topoisomerase (anti-Scl70), 
anti-mitochondrial, anti-thyroid, anti-neutrophil cytoplasmic 
antibody (ANCA), anti-nucleosome, anti-fi laggrin, anti-liver-
kidney microsome antibodies (anti-LKM) and anti-adrenal 
antibody. Articles that assessed only rheumatoid factor and 
anti-citrullinated protein antibodies (ACPA) were excluded 
from this review.
Results
A total of 998 articles were found, of which 79 abstracts were 
initially selected and subsequently, 24 full articles. Of the 998 
articles found, 919 abstracts were excluded because although 
they were retrieved by the electronic search, they did not meet 
the inclusion criteria (Fig. 1). In spite of the thorough search of 
cross-references in the selected articles, no additional article 
was found. A total of 760 patients were studied and articles 
from the following countries were assessed: Belgium, Canada, 
France, Israel, Italy and Sweden (Table 1).
ANA was evaluated in almost all studies selected in this 
systematic review (Table 1). The total number of patients with 
ANA assessment was 695, of which 199 (28.6%) had reactive 
ANA before infl iximab use. After the medication use (on aver-
age after six months, as only one study had a three-month 
duration), the total number of patients with reactive ANA was 
469 (67.5%), i.e., there was a variation of 38.9% of reactive pa-
tients before and after infl iximab use (Table 2). 
Regarding the anti-dsDNA, two studies did not evaluate it 
separately (Table 1). Thus, the total number of evaluated cases 
was 669. In the beginning, before infl iximab use, only eight 
cases (1.2%) were reactive, whereas after treatment, 117 (17.5%) 
patients were reactive, with a variation of 16.2% (Table 2).
As for anti-ssDNA, only two studies assessed this antibody. 
Vermeire et al.,26 in 2003, found this antibody in approximate-
ly 14% (17 of a total of 125) patients after infl iximab use for 12 
months. Comby et al.,16 in 2006, showed that after six months 
of infl iximab use there was a 12% increase in the number of 
patients with high titers of anti-ssDNA. 
The studies that evaluated the total anti-ENA (Table 1) 
showed no case before or after treatment (Table 2). All four 
studies (Table 1) that analyzed saline-extractable antigens 
(anti-ENA) separately found a total of 208 cases, with anti-Ro 
varying from four (1.9%) to fi ve (2.4%) cases before and after 
infl iximab, respectively. As for anti-RNP, there was only one 
case (0.6%) before and 12 (7.3%) cases after infl iximab use, 
with a 6.7% (n = 165) variation. Before medication there were 
two patients (1.2%) with reactive anti-La and after medica-
tion that number increased to only three cases (1.8%), with a 
0.6% variation (n = 165). There was only one case (0.7%) with 
reactive anti-Sm (n = 139), with no alterations after treatment. 
Six studies (Table 1) evaluated aCL in a total of 222 patients. 
Before treatment, 21 (9.5%) cases were reactive, but at the end 
of treatment 49 (22%) of cases were reactive, with a variation 
of 12.5%  (Table 2). There were no cases of anti-Beta 2 GP1 be-
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Table 1 – Epidemiologic, disease and autoantibody data of the analyzed studies. 
Author/ year Country N F/M Age mean 
(years)
Diseases Time of 
disease 
(years)
Study duration 
(months)
Autoantibodies
Allanore13 
2004
France 59 54/05 54 (41-68) RA 14 (05-23) 7.5 ANA, anti-dsDNA, anti-histone, 
total anti-ENA 
Bobbio-
Palavicini14 
2004
Italy 30 24/06 57 (48-66) RA 9 (1-17) 18 ANA, anti-dsDNA, aCL 
Caramaschi15 
2006
 Italy 43 37/06 52 (40-64) RA 14 (5-23) 12 ANA, anti-dsDNA, ANCA, anti-
mitochondrial, anti-thyroid, 
anti-Ro
Comby16 2006  France 58 44/14 54 (42-66) RA 13 (04-22) 3 ANA, anti-dsDNA, anti-ssDNA
DeRycke17 
2003
Belgium AR 62
EA 35
38/24 
12/23
54 (32-76) 
47 (29-66)
RA, AS — AR 7.5
EA 8.5
ANA, anti-dsDNA, anti-histone, 
anti-nucleosome, anti-Sm, anti-
RNP, anti-Ro, anti-La
Elkayam18 2005 Israel 26 17/09 51 (27-71) RA — 3 ANA, anti-dsDNA,  aCL, ANCA, 
anti-RNP, anti-Sm, anti-Ro, anti-
La, anti-SCL70, anti-peroxidase, 
anti-histone, total anti-ENA 
Erikson19 2005 Sweden 53 43/10 55 (26-79) RA 14 (2-37) 7.5 (3.5-13.5) ANA, anti-dsDNA aCL, total 
anti-ENA,  anti-nucleosome, 
anti-mitochondrial, anti-
smooth muscle, anti-histone, 
anti-proteinase 3, anti-
myeloperoxidase
Ferraro-Peyret20 
2004
France AR 24
EA 15
16/08 
04/11
56 (26-77) 
41 (26-57)
RA, AS 12 (3-32) 17 
(6-30)
18 ANA, anti-DNAds  aCL, anti-
B2GPI, ANCA, anti-LKM, anti-
mitochondrial, anti-smooth 
muscle, anti-peroxidase, anti-
thyroglobulin, anti-adrenal
Hoxha21 2006 Italy AR 30
 EA 30
AR 24/06 
EA 05/25
AR 52 (39-65)
EA 35 (23-47)
RA, AS AR 12 (05-18)
EA 10 (02-18)
AR 29-53 
EA 06-26
ANA, anti-dsDNA  total anti-ENA 
Jondosttir22 
2004
Sweden 65 — — RA — 12 aCL
Louis23 2003 Canada 42 05/37 53 (40-66) RA, AS, PA — 6 ANA, anti-dsDNA, anti-Sm, anti-Ro, 
anti-La, anti-RNP 
Nancey24 2005 France 35 24/11 36 (19-71) Crohn’s 10 (03-24) 12 ANA, anti-dsDNA  aCL, anti-B2GPI, 
anti-mitochondrial, anti-smooth 
muscle, anti-fi laggrin, anti-LKM, 
anti-thyroid 
Sellam25 2005 France 28 18/10 42 (28-56) AS 10 (5-15) 8 ANA, anti-dsDNA, anti-histone, 
total anti-ENA 
Vermeire26 
2003
Bélgica 125 82/43 34 (28-43) Crohn’s — 12 ANA, anti-dsDNA, anti-ssDNA, 
anti-histone, total anti-ENA 
Total 760
RA, rheumatoid arthritis; AS, ankylosing spondylitis; PA, psoriatic arthritis; ANA, antinuclear antobody; anti-dsDNA, anti-native or double-strand 
DNA; anti-ssDNA, Anti-Single Stranded DNA; aCL, anticardiolipin; ANCA, Anti-neutrophil cytoplasmic antibodies; anti-Beta2GP1, anti beta-2-
glycoprotein-1 antibody; anti-ENA, Extractable Nuclear Antigen antibodies; anti-SCL70, anti-topoisomerase; anti-RNP, anti-ribonucleoprotein; 
anti-LKM, anti-liver-kidney microsome antibodies
Table 2 – Variation of autoantibodies before and after infl iximab use.
Autoantibody n Before treatment After treatment Variation (%)
ANA 695 199 (28.6%) 469 (67.5%) 38.9
Anti-dsDNA 669 8 (1.2%) 117 (17.5%) 16.3
Total  anti-ENA 351 0 0 0
aCL 222 21 (9.5%) 49 (22%) 12.5
Anti-beta 2 GP1 74 0 6 (8.1%) 8.1
Anti-histone 388 48 (12%) 116 (30%) 18
Anti-nucleosome 147 9 (6.1%) 22 (15%) 8.9
M ANCA 108 0 7 (6.5%) 6.5
ANA, antinuclear antibody; anti-dsDNA, anti-native or double-strand DNA; anti-ssDNA, Anti-Single Stranded DNA; anti-ENA, Extractable Nuclear 
Antigen antibodies; aCL, anticardiolipin; anti-Beta2GP1, anti beta 2 glycoprotein 1 antibody; ANCA, Anti-neutrophil cytoplasmic antibodies.
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Table 3 – Data of patients with infl iximab-induced lupus erythematosus.
Studies Time after 
infl iximab
Clinical signs Autoantibodies Evolution
Bobbio-Palavicinni14 30 weeks Moderate arthritis and malar rash Anti-dsDNA Resolution a few weeks after withdrawal
Pleuropericarditis Anti-dsDNA
Comby16 18 months Migratory  arthralgia, asthenia ANA > 1:1280; 
anti-dsDNA IgG
Symptom duration for one month after 
infl iximab withdrawal; control after 
corticosteroid; ANA remained persistently 
high
Elkayam18  3 infusions Myalgia, arthralgia, fever > 38 °C, 
rash in the legs and arms 
ANA, anti-histone Resolution after infl iximab and prednisone 
withdrawal
5 infusions Fever, myalgia, polyarthralgia ANA, anti-histone Infl iximab and prednisone withdrawal for 
one week
Eriksson19 Myalgia, arthritis Anti-histone, 
anti-dsDNA IgG, 
consumption of 
complements C3 and 
C4, leukopenia
Improvement after a few weeks of infl iximab 
withdrawal without prednisone
Eriksson19 54 weeks Malar  rash, leukopenia, arthralgia 
and vasculitis in upper-limb 
distal extremities
Anti-dsDNA, 
anti-nucleosome
Nancey24  3 infusions Malar rash, polyarthralgia ANA and anti-dsDNA Spontaneous recovery after a few weeks 
without infl iximab or corticosteroids 
Vermeire26 1 infusion Polyarthralgia, myalgia 
and malar rash 
ANA, anti-dsDNA and 
anti-histone
Symptoms disappeared after infl iximab 
withdrawal; reactive ANA even after a year, 
but with lower titers 
 1 infusion Arthralgia and malar rash  ANA 1:640
ANA, anti-nuclear antibody; anti-dsDNA, anti-double-stranded DNA.
fore infl iximab use (n = 74 in two studies), but after using the 
medication, the variation was 6.5% (seven cases) (Table 2).
As for the anti-histone, it was evaluated by six studies (Ta-
ble 1), with a total of 388 cases. Before the biological agent, 48 
(12%) cases were reactive, but after the medication, 116 (30%) 
patients were reactive, within a variation of 18% (Table 2). In 
the study by Vermeire et al.,26 no patient had anti-histone an-
tibody before, but 1.6% of the cases (two in a total of 125) in-
creased their titers and developed infl iximab-induced lupus 
(IIL) after using infl iximab for 24 months (in addition to the 
presence of anti-histone, there was also increase in the titers 
of ANA and anti-dsDNA). In 2004, Alanore et al.13 evaluated 
the IgM and IgG isotypes separately, showing that, after using 
the medication, the IgM isotype increased signifi cantly after 6 
weeks, but with no clinical signifi cance.
The anti-nucleosome antibody was assessed by two stud-
ies (Table 1), with a total of 147 cases, in which 9 (6.1%) were 
reactive before medication and 22 (26%) after the use of infl ix-
imab (Table 2), but with no clinical signifi cance. 
The anti-neutrophil cytoplasmic antibody (ANCA) was 
evaluated in three studies (n = 108) (Table 1). Before infl ix-
imab, there were no cases of ANCA reactivity, with a variation 
of 6.5% (seven cases) after biological agent use (Table 2). There 
was no correlation with vasculitis in any of the cases. Eriks-
son et al.19 in 2005, separately evaluated anti-proteinase 3 and 
anti-myeloperoxidase antibodies, but there was no reactivity 
in any case before or after the use of infl iximab.
Four studies also evaluated other autoantibodies, namely: 
anti-mitochondrial, anti-smooth muscle, anti-fi llagrin, anti-
liver-kidney microsomal (anti-LKM), anti-peroxidase thyroid, 
thyroglobulin and anti-adrenal autoantibodies. None of the 
studies showed a signifi cant variation in these antibodies. Of 
the 760 cases evaluated in all studies, only 10 reported pa-
tients (1.3%) with probable IIL (Table 3). 
Discussion
This systematic review provides information on infl iximab-
induced autoantibodies and lupus erythematosus. The great-
est diffi culty in correlating autoantibodies is the lack of stan-
dardization, as each study used a different method. When the 
method used was the same, the autoantibody kits or ANA cut-
offs were different, preventing a reliable comparison. 
Our search included only phase-IV studies published 
from 2003 to 2006 (studies dating from previous years were 
excluded for not meeting the parameters used in this sys-
tematic review) (Figure 1). Viana et al.,27 in 2010, performed a 
study in patients with psoriatic arthritis showing that anti-
TNF therapy induced changes in ANA in one third of patients 
(n = 23) and most evaluated autoantibodies (anti-nDNA, 
anti -Ro, anti-La, aCL, anti-histone and rheumatoid factor) 
did not react after biologic therapy. Although the study was 
well performed, we could not include it in this review, as 
the biological agents were evaluated together (infl iximab, 
adalimumab and etanercept) and the results of patients us-
ing infl iximab only were not reported (Fig. 1), although they 
were the majority (19 of 23 patients). The most recent study 
evaluated in our search was the one by Hoffmann et al.,28 in 
2011, regarding the use of infl iximab in psoriasis. However, it 
could not be included in this review either, as some patients 
had used other biological agents before infl iximab (Fig. 1), 
but were not separated from the total group, so we could not 
use their data in our calculations. 
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To calculate the percentage of autoantibodies found, we 
used as fi nal result the period in which the antibodies were 
more reactive for studies that measured the antibodies sev-
eral times during each visit, or, in the case of loss of patients, 
we used the period where there were more patients. 
We chose studies of which duration was of at least three 
months, as there have been reports of this being the mini-
mum time for autoantibody induction by infl iximab.18,22 How-
ever, Nancey et al.,24 in 2005, showed that there has been 
persistent induction of ANA and anti-dsDNA even after the 
second infusion of the drug.
This systematic review found that the most common au-
toantibodies evaluated in the studies were ANA, anti-dsDNA, 
total anti-ENA and anti-histone. In fact, several studies chose 
to evaluate total anti-ENA and, in case of a reactive result, the 
autoantibodies would then be evaluated separately. However, 
as observed in our study that no patient reacted with the anti-
ENA antibodies (n = 351) (Table 2), the number of patients that 
had these autoantibodies measured was lower than those 
who had other autoantibodies measured. 
The autoantibody associated with antiphospholipid anti-
body syndrome (aCL) was described in 222 patients, but there 
was no clinical signifi cance (no patient developed thrombotic 
episode). There were no cases of anti-Beta 2 GP 1 before infl ix-
imab use (n = 74 in both studies), but after using the medica-
tion, the variation was 6.5% (seven cases) (Table 2), also with 
no thrombotic events. The study of Bobbio-Palaviccini et al.29 
in 2009 demonstrated a signifi cant increase in anti-B2GP1 af-
ter infl iximab use for 1-2 years, which did not happen with 
the other tested anti-TNF agents (etanercept and adalimum-
ab). However, there was no association with clinical manifes-
tations, either. 
Regarding the development of autoimmune diseases, even 
for studies that showed a signifi cantly higher ANA and other 
autoantibodies comparing the periods before and after inf-
liximab, the latter did not induce any disease, except those 
10 cases of IIL. In these patients, the most commonly found 
antibodies were ANA, anti-dsDNA and anti-histone, as dem-
onstrated by several reports in the literature.30-32 The most 
common clinical fi ndings were arthralgia and myalgia, ac-
cording to several case reports on this issue. Only one patient 
had serositis.
Autoantibody induction was not associated with the un-
derlying disease, as the studies in this review evaluated pa-
tients with several autoimmune and infl ammatory diseases 
(RA, AS, PA, Crohn’s), generating multiple autoantibodies, re-
gardless of the disease in question, but the non-development 
of other diseases suggests that it is only an epiphenomenon, 
and in most cases, these autoantibodies should not be patho-
genic. Perhaps if methodologies that assessed more patho-
genic antibodies were used, such as multiplex equipment, the 
result would be quite different. That is, we believe autoanti-
bodies would be found in only a few cases. 
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